BioVaxys CEO James Passin joins Natalie Stoberman from the Proactive newsroom to share the announcement of its finalized United States distribution agreement with Procare Health for Papilocare and Oral Immunocaps treatments.
Papilocare is the world's first and only patented vaginal gel product with clinical evidence to prevent and treat HPV-dependent cervical lesions. Immunocaps, which can be used on its own or together with Papilocare, is an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.